Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants

被引:19
作者
Van der Linden, Dimitri
Hainaut, Marc
Goetghebuer, Tessa
Haelterman, Edwige
Schmitz, Veronique
Maes, Philip
Peltier, Alexandra
Levy, Jack
机构
[1] ULB Brussels, Dept Pediat, Ctr Hosp Univ St Pierre, B-1000 Brussels, Belgium
[2] Univ Liege, CHR La Citadelle, Liege, Belgium
[3] AZM Koningin Paola Kinderziekenhuis, Antwerp, Belgium
关键词
infants; highly active antiretroviral therapy; HIV; viral load;
D O I
10.1097/01.inf.0000258626.34984.eb
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Each of the 17 vertically infected infants born to HIV-1-infected mothers in Belgian HIV reference centers since 1996 was treated with a combination of 3 reverse transcription inhibitors as soon as the diagnosis was established. Treatment was initiated in all patients before 66 days of life. Twelve patients, including 11/13 infants treated with the combination of zidovudine, lamivudine and nevirapine, expenenced a complete viral suppression (< 50 copies/mL) with their first drug regimen. At last follow-up, 12 patients were asymptomatic, 2 were CDC stage A and 3 were stage B; 15 had HIV-1 RNA levels of < 50 copies/mL and 14 had >= 25% CD4 lymphocytes. These results suggest that early initiation of treatment with 3 reverse transcription inhibitors is highly effective to inhibit viral replication and to prevent clinical and immunologic progression of HIV infection in vertically infected infants.
引用
收藏
页码:359 / 361
页数:3
相关论文
共 9 条
[1]  
Aboulker JP, 2004, AIDS, V18, P237, DOI [10.1097/00002030-200401230-00013, 10.1097/01.aids.0000111388.02002.6b]
[2]  
BANCHE S, 1997, J ACQ IMMUN DEF SYND, V14, P442
[3]   Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. [J].
Chiappini, E ;
Galli, L ;
Tovo, PA ;
Gabiano, C ;
Gattinara, GC ;
Guarino, A ;
Baddato, R ;
Giaquinto, C ;
Lisi, C ;
de Martino, M .
AIDS, 2006, 20 (02) :207-215
[4]   Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1 [J].
Faye, A ;
Le Chenadec, M ;
Dollfus, C ;
Thuret, I ;
Douard, D ;
Firtion, G ;
Lachassinne, E ;
Levine, M ;
Nicolas, J ;
Monpoux, F ;
Tricoire, J ;
Rouzioux, C ;
Tardieu, M ;
Mayaux, MJ ;
Blanche, P .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (11) :1692-1698
[5]  
Gray L, 2001, PEDIATRICS, V108, P116, DOI 10.1542/peds.108.1.116
[6]   Seroreversion in children infected with HIV type 1 who are treated in the first months of life is not a rare event [J].
Hainaut, M ;
Peltier, CA ;
Goetghebuer, T ;
Van der Linden, D ;
Marissens, D ;
Zissis, G ;
Levy, J .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (12) :1820-1821
[7]   Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1 [J].
Hainaut, M ;
Peltier, CA ;
Gérard, M ;
Marissens, D ;
Zissis, G ;
Levy, J .
EUROPEAN JOURNAL OF PEDIATRICS, 2000, 159 (10) :778-782
[8]   A trial of three antiretroviral regimens in HIV-1-infected children [J].
Luzuriaga, K ;
McManus, M ;
Mofenson, L ;
Britto, P ;
Graham, B ;
Sullivan, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (24) :2471-2480
[9]   Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection [J].
Luzuriaga, K ;
Bryson, Y ;
Krogstad, P ;
Robinson, J ;
Stechenberg, B ;
Lamson, M ;
Cort, S ;
Sullivan, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (19) :1343-1349